BrainStorm Stem Cell Therapy Treatment Shown To Be More Effective Than Other Current Potential Stem Cell Treatments

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--Nov 9,
2009 - BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading
developer of adult stem cell technologies and therapeutics, is
pleased to announce that the company's therapeutic approach for
treating neurodegenerative diseases was shown to be superior to
other current potential stem cell treatments.

In a scientific paper published in the Israel Medical
Association Journal, Ofer Sadan, Eldad Melamed and Daniel Offen,
from Tel Aviv University, show the migratory capacity of
Neurotrophic Factor Stem Cells (NTF-SC) in animal models of
Parkinson's disease and Huntington disease. The study demonstrated
that in a rat model for Parkinson's disease, the efficacy of NTF-SC
was superior to that of mesenchymal stem cells in terms of
behavioral, biochemical and histological indices.

“The results of this study show that the NTF-SC based
treatment is efficacious due to NTF secretion and the stem cell's
migratory capabilities. Since our novel technology is clinically
compatible and safe, the study suggests that in the future, cell
therapy based on the transplantation of NTF-SC derived from
autologous human mesenchymal stem cells should become a preferable
option in the treatment of neurodegenerative diseases,”
commented Professor Daniel Offen, Brainstorm's chief scientific
advisor.

“This study demonstrates that Brainstorm's approach in
differentiating adult mesenchymal stem cells into NTF-SC, will
provide the most effective approach for the treatment of
neurodegenerative diseases via the use of stem cells,” said
Rami Efrati, CEO of Brainstorm. “As we near clinical trials,
the Company and its scientific team will continue to study how our
technology and methodology can be further utilized with other
neurodegenerative diseases.”

BrainStorm Cell Therapeutics Inc. is an emerging company
developing adult stem cell therapeutic products, derived from
autologous (self) bone marrow cells, for the treatment of
neurodegenerative diseases. The patent pending technology is based
on discoveries made by the scientific team led by Professor Eldad
Melamed, former Head of Neurology at Rabin Medical Center, and cell
biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory
at the Felsenstein Medical Research Center of Tel-Aviv University.
The technology allows for the differentiation of bone
marrow-derived stem cells into functional neurons and astrocytes,
as demonstrated in animal models. The Company holds rights to
develop and commercialize the technology through an exclusive,
worldwide licensing agreement with Ramot at Tel Aviv University
Ltd., the technology transfer company of Tel-Aviv University. The
Company's current focus is on ALS, although its technology has
promise for treating several other diseases including MS,
Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve
risks and uncertainties that could cause BrainStorm Cell
Therapeutics Inc.'s actual results to differ materially from those
stated or implied by such forward-looking statements, including
BrainStorm's ability to complete its equity financing transactions
previously disclosed. The potential risks and uncertainties
include, among others, risks associated with BrainStorm Cell
Therapeutics Inc.'s limited operating history, history of losses
and expectation to incur losses for the foreseeable future; minimal
working capital and difficulty raising additional capital,
dependence on its license to Ramot's technology; ability, together
with its licensor, to adequately protect the technology; dependence
on key executives and on its scientific consultants; ability to
identify, negotiate and successfully implement strategic partnering
relationships; ability to complete clinical trials successfully and
to obtain required regulatory approvals; competition with
companies, some of which have greater resources and experience in
developing and obtaining regulatory approval for treatments in
BrainStorm Cell Therapeutics Inc.'s market; the limited public
trading market for BrainStorm Cell Therapeutics Inc.'s stock which
may never develop into an active market; and other factors detailed
in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-K,
quarterly reports on Form 10-Q, current reports on Form 8-K and
other filings with the Securities and Exchange Commission available
at
http://www.sec.gov/ or by request to the Company. The Company
does not undertake any obligation to update forward-looking
statements made by us.